clinical trial – Page 230 – Communicable Diseases Research

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Research

Published on 2020-06-092022-10-05
Journal: Nature [Category] SARS, 비임상, 임상, 진단, 치료제,

Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China

Article

Published on 2020-06-092022-10-04
Journal: Virus research [Category] SARS, 치료법, 치료제,

[키워드] ACE2, angiotensin converting enzyme II ACE2angiotensin converting enzyme II activities acute respiratory distress syndrome Adverse reactions angiotensin converting enzyme II ARDS, acute respiratory distress syndrome ARDSacute respiratory distress syndrome articles Biological Biological products C-reactive protein cellular Characteristics Chemical drugs China China National Knowledge Infrastructure Chinese chronic obstructive pulmonary disease clinical trial clinical trials CNKI CNKI, China National Knowledge Infrastructure CNKIChina National Knowledge Infrastructure convalescent plasma COPD, Chronic obstructive pulmonary disease COPDchronic obstructive pulmonary disease Coronavirus disease 2019 COVID-19 COVID-19, Coronavirus disease 2019 COVID-19coronavirus disease 2019 CP, convalescent plasma CPconvalescent plasma CRP, C-reactive protein CRPC-reactive protein database dengue virus DENV, dengue virus DENVdengue virus drug drugs EC50, half effective concentration EC50half effective concentration effective drugs Effects Efficacy and safety Fangfeng Tongsheng Pill FFTS, Fangfeng Tongsheng Pill FFTSFangfeng Tongsheng Pill filtered GA, glycyrrhizic acid GAglycyrrhizic acid glycyrrhizic acid Government half effective concentration Health HIV, Human immunodeficiency virus HIVhuman immunodeficiency virus HSBD, Huashi Baidu Prescription HSBDHuashi Baidu Prescription Huashi Baidu Prescription Human immunodeficiency virus Huoxiang Zhengqi HXZQ, Huoxiang Zhengqi HXZQHuoxiang Zhengqi IFN-α, interferon-α IFN-αinterferon-α indications Infrastructure ingredient injection Interferon-α JHQG, Jinhua Qinggan Granule JHQGJinhua Qinggan Granule Jiedu Capsule Jinhua Qinggan Granule large sample LHQW, Lianhua Qingwen Capsule LHQWLianhua Qingwen Capsule Lianhua Qingwen capsule medication MERS-CoV, Middle East respiratory syndrome coronavirus MERS-CoVmiddle east respiratory syndrome coronavirus Mesenchymal stem cells Middle East respiratory syndrome Coronavirus MNV, murine norovirus MNVmurine norovirus MSCs, mesenchymal stem cells MSCsmesenchymal stem cells murine norovirus natural killer NCP, novel coronavirus pneumonia NCPnovel coronavirus pneumonia NK, natural killer NKnatural killer Novel coronavirus novel coronavirus pneumonia pharmacological Pneumonia Potential QFPD, Qingfei Paidu Decoction QFPDQingfei Paidu Decoction Qingfei Paidu decoction Randomized controlled trials RCTs, randomized controlled trials RCTsrandomized controlled trials researcher respiratory syncytial virus ribofuranosyl-5′-triphosphate RSV, respiratory syncytial virus RSVrespiratory syncytial virus RTP, ribofuranosyl-5′-triphosphate RTPribofuranosyl-5′-triphosphate SARS-CoV-2 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 SARS-CoV-2severe acute respiratory syndrome coronavirus 2 SARS-CoV, severe acute respiratory syndrome coronavirus SARS-CoVsevere acute respiratory syndrome coronavirus searched severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Shufeng SFJD, Jiedu Capsule Shufeng SFJDJiedu Capsule stem cells TCM TCMs, traditional Chinese medicines TCMstraditional Chinese medicines therapeutic effect TJQW, Toujie Quwen Granule TJQWToujie Quwen Granule Toujie Quwen granule Traditional Chinese medicine traditional Chinese medicines treat Treatment Vaccines XFBD, Xuanfei Baidu Decoction XFBDXuanfei Baidu Decoction Xuanfei Baidu Decoction
[DOI] 10.1016/j.virusres.2020.198057 PMC 바로가기 [Article Type] Article

The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial

Letter

Published on 2020-06-082022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 48 hour 48 hours Activation Administered adverse event African age allergy analyzed Angola Antiviral approved ARMS Barcelona baseline blinded block Cerebrovascular disease chain chest X-ray childbearing chronic clinical care clinical trial co-morbidity conducted contraceptive method control group coronary disease cough country COVID-19 COVID-19 disease COVID-19 patient criteria Critical current CYP3A4 death detectable determine diagnosed with COVID-19 disease dissemination dose double-blind drug early treatment Efficacy element Endemic EudraCT excluded eye Factor Fever flow cytometry Follow-up visit Frequency Gabon global health groups history home visit Identified IgA IgA level IgG IgM immune response Immunity immunology immunomodulatory IMPROVE in vivo Infection Inflammatory inhibitor interfere investigator involved Isolation Ivermectin laboratory parameter Loa loa magnitude marker median Nasopharyngeal swab nasopharyngeal swab PCR negative neoplasm Nigeria no risk number objective outcome participant Patient Patient care patients PCR PCR cycle physical Placebo placebo group placebo-controlled Pneumonia positive positive SARS-CoV-2 PCR post-menopausal Potential pregnancy test pregnant women progression proportion protocol public health pulmonary random randomised randomised controlled trial randomization randomization list Randomized Rapid diagnostic test reaction receive recent recruited reduce Registered renal resident risk Ritonavir Safe Sample size SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2-specific T cell secondary sequence Seroconversion severe disease severity single center single dose Spain status Study protocol subject submitted surgical Symptom symptom onset the patient the SARS-CoV-2 threshold transcriptomics Transmission transmission-blocking Travel treated patient treated patients Treatment treatment group Trial unblinding Viral load virus vulnerable population website with mild disease women
[DOI] 10.1186/s13063-020-04421-z PMC 바로가기 [Article Type] Letter

Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review

Review

Published on 2020-06-082022-10-31
Journal: Nutrients [Category] COVID-19, SARS,

Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-06-082022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] activity adverse event allergic reaction anti-SARS-CoV-2 anti-SARS-CoV-2 antibody Anti-SARS-CoV-2 plasma Anti-viral blinded Blood blood product center Chest radiography Clinical improvement Clinical outcome clinical status clinical trial clinician collected Columbia University control arm convalescent plasma coronavirus COVID-19 COVID-19 symptom criteria cumulative Date defined Dilution discharge dissemination Donor ECMO Efficacy Efficacy and safety element evaluate Evaluating Evidence extracorporeal membrane oxygenation hazard hazard ratio HBV HCV HIV hospital Hospitalized hospitalized patient IgA deficiency immune incidence include Infection Influenza Invasive mechanical ventilation mechanical ventilation multi-organ failure nasopharyngeal Nasopharyngeal swab New York Non-invasive number objective occur oropharyngeal swab outcome oxygen saturation participant Participants patients hospitalized PCR test PCR-negative per-protocol analysis peripheral capillary plasma platform post-hoc analysis Pregnancy primary endpoint protocol randomization Randomized Randomized controlled trial randomized, controlled trial randomly permuted block receive Registered Remdesivir requiring high-flow oxygen requiring supplemental oxygen Research Respiratory failure retrospective Ritonavir safety endpoint Sample size SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection screened Serious Adverse Event seven-point ordinal scale severe COVID-19 severe SARS-CoV-2 severely ill adult single-center spike trimer SpO2 status study participant study period Study protocol supplemental oxygen tested therapy transfused Treatment treatment for COVID-19 Trial undergo USA Version Volunteer Wald test website with COVID-19 World Health Organization ZIKV
[DOI] 10.1186/s13063-020-04422-y PMC 바로가기 [Article Type] Letter

Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review

Research

Published on 2020-06-082022-10-28
Journal: BJGP Open [Category] COVID-19,

Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients

Perspective

Published on 2020-06-072022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] acute respiratory distress caused clinical clinical setting clinical testing clinical trial coronavirus COVID-19 Cytokine storm drug candidate effective evaluate expected function global pandemic global public health Host IL-6 immune Infection Inflammatory cytokine inhibitor interferon Jak limit lymphopenia mechanism monoclonal antibody novel coronavirus SARS-CoV-2 Open-label Patient predicted provide Randomized reduce Remdesivir replication/transcription machinery responses RNA-dependent RNA polymerase senescence severe COVID-19 Signaling silibinin Spain STAT3 storm syndrome T-cell targeting the cytokine storm therapeutic efficacy Viral load virus replication
[DOI] 10.3390/jcm9061770 PMC 바로가기 [Article Type] Perspective

COVID-19 Clinical Research

Article

Published on 2020-06-072022-10-29
Journal: Journal of cellular signaling [Category] COVID-19,

Clinical Perspective on 2019 Novel Coronavirus Pneumonia: A Systematic Review of Published Case Reports

Internal Medicine

Published on 2020-06-072022-10-31
Journal: Cureus [Category] COVID-19,

[키워드] 2019 novel coronavirus 2019-nCoV acute respiratory distress antiviral drug ARDS Case report clinical Clinical improvement clinical trial conducted Corona pandemic COVID-19 pneumonia COVID-2019 death disease effective High-risk patients hospital IMPROVE interstitial pneumonia Isolation Laboratory management management guideline Mild mild illness moderate multi-viral pneumonia novel novel corona virus outcome pandemic pathology Patient Pneumonia randomized clinical trial RCTs reducing mortality Remdesivir report review severe pneumonia shown supportive care syndrome systematic review Transmission Treatment treatment guideline Wuhan, China
[DOI] 10.7759/cureus.8488 PMC 바로가기 [Article Type] Internal Medicine

The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hours acid Administered Affect analyst Anti-viral anticipated Beijing block block randomization Blood Body Capital cardiovascular system Care center changed Chinese clinical clinical manifestation Clinical outcome Clinical studies clinical trial college Complete condition Consent control group Corona Corona virus cough COVID-19 criteria curative Diagnosis discharge discharged disease Diseases dissemination dose drug Ebola virus element eligibility criteria enrolled expected experimental group Favipiravir female Follow-up form hepatology history hospital include Including Infection Infectious disease Informed inhibit investigators kidney lack lactating women life-threatening liver Loss male Measures mechanism Medicine Mental Disorders Nasopharyngeal swab nasopharyngeal swabs not blinded nucleic acid nucleic acid test number objective open label oral administration outcome outcome assessors Oxygen therapy parallel group participant Participants Patient plan poor compliance positive protocol Public pulmonary randomised randomised controlled trial randomization system Randomized controlled trial Randomly recruited recruitment reduced Regular Reinfection Research researcher respiratory specimen response returned RNA-dependent RNA polymerase routine screening visit second secondary severe adverse events severity severity of symptoms Shenzhen specimens sputum status Study protocol subject Symptom Symptoms System temperature Test tested therapeutic efficacy throat swabs Traditional Treatment treatment for COVID-19 treatment group Trial uncontrolled university variety viral nucleic acid virus Web website Withdrawal Wuhan
[DOI] 10.1186/s13063-020-04430-y PMC 바로가기 [Article Type] Letter